Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant

Safety and efficacy of allogeneic anti-CD19 chimeric antigen receptor T cells (CAR-T cells) in persons with CD19-positive B-cell acute lymphoblastic leukemia (B-ALL) relapsing after an allotransplant remain unclear. Forty-three subjects with B-ALL relapsing post allotransplant received CAR-T cells w...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Cheng, Wang, Xiao-Qi, Zhang, Rong-Li, Liu, Fang, Wang, Yi, Yan, Zhi-Ling, Song, Yong-Ping, Yang, Ting, Li, Ping, Wang, Zhen, Ma, Ying-Ying, Gao, Lei, Liu, Yao, Gao, Li, Kong, Pei-Yan, Liu, Jun, Tan, Xu, Zhong, Jiang F., Chen, Yu-Qing, Liang, Ai-Bin, Ren, Jin-Hua, Li, Zhen-Yu, Cao, Jiang, Gao, Quan-Li, Zhou, Jian, Gao, Ying, Zhang, Ding, Fan, Fang-Yi, Han, Ming-Zhe, Gale, Robert Peter, Zhang, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179843/
https://www.ncbi.nlm.nih.gov/pubmed/33077866
http://dx.doi.org/10.1038/s41375-020-01056-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179843/
https://www.ncbi.nlm.nih.gov/pubmed/33077866
http://dx.doi.org/10.1038/s41375-020-01056-6

Ejemplares similares